E Hawk

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey
    E Hawk
    Gastrointestinal and Other Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
    Cancer Epidemiol Biomarkers Prev 9:523-7. 2000
  2. ncbi request reprint What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment
    Ernest Hawk
    Office of Centers, Training, and Resources, National Cancer Institute OD, Bethesda, MD, USA
    Semin Oncol 33:S6-9. 2006
  3. ncbi request reprint Colorectal cancer prevention
    Ernest T Hawk
    GI and Other Cancers Research Group, National Cancer Institute, 6130 Executive Boulevard, Suite 2141, Bethesda, MD 20892 7322, USA
    J Clin Oncol 23:378-91. 2005
  4. ncbi request reprint Prevention and therapy of colorectal cancer
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Med Clin North Am 89:85-110, viii. 2005
  5. ncbi request reprint Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention
    Ernest T Hawk
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892 7317, USA
    Cancer Chemother Biol Response Modif 21:759-89. 2003
  6. ncbi request reprint Colorectal cancer chemoprevention--an overview of the science
    Ernest T Hawk
    Gastrointentinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute NIH, EPN Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Gastroenterology 126:1423-47. 2004
  7. pmc Aspirin: still learning about the wonder drug
    E T Hawk
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892, USA
    Gut 52:1535-6. 2003
  8. ncbi request reprint Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
    Prog Exp Tumor Res 37:210-42. 2003
  9. ncbi request reprint Epidemiology and prevention of colorectal cancer
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Surg Clin North Am 82:905-41. 2002
  10. ncbi request reprint Chemoprevention of colorectal carcinogenesis
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Int J Clin Oncol 7:2-26. 2002

Detail Information

Publications24

  1. ncbi request reprint Male pattern baldness and clinical prostate cancer in the epidemiologic follow-up of the first National Health and Nutrition Examination Survey
    E Hawk
    Gastrointestinal and Other Cancer Research Group, Division of Cancer Prevention, National Cancer Institute, NIH, Bethesda, Maryland 20892 7322, USA
    Cancer Epidemiol Biomarkers Prev 9:523-7. 2000
    ..50 (95% confidence interval, 1.12-2.00) and was similar regardless of the severity of baldness at baseline and was independent of other risk factors, including race and age. MPB seems to be a risk factor for clinical prostate cancer...
  2. ncbi request reprint What is the future of oncology? National Cancer Institute initiatives to improve research, development, and implementation in cancer prevention and treatment
    Ernest Hawk
    Office of Centers, Training, and Resources, National Cancer Institute OD, Bethesda, MD, USA
    Semin Oncol 33:S6-9. 2006
    ....
  3. ncbi request reprint Colorectal cancer prevention
    Ernest T Hawk
    GI and Other Cancers Research Group, National Cancer Institute, 6130 Executive Boulevard, Suite 2141, Bethesda, MD 20892 7322, USA
    J Clin Oncol 23:378-91. 2005
    ..The threshold for tolerating toxicities is very low in asymptomatic individuals at minimally increased risk for colorectal neoplasia...
  4. ncbi request reprint Prevention and therapy of colorectal cancer
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Med Clin North Am 89:85-110, viii. 2005
    ..These advances substantiate target-driven approaches to cancer prevention and treatment, and provide fruitful opportunities for future investigations...
  5. ncbi request reprint Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention
    Ernest T Hawk
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892 7317, USA
    Cancer Chemother Biol Response Modif 21:759-89. 2003
  6. ncbi request reprint Colorectal cancer chemoprevention--an overview of the science
    Ernest T Hawk
    Gastrointentinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute NIH, EPN Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Gastroenterology 126:1423-47. 2004
    ..Innovative research models include the nesting of prevention end points within cancer treatment trials and within trials testing promising preventive compounds intended for nononcologic indications...
  7. pmc Aspirin: still learning about the wonder drug
    E T Hawk
    National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892, USA
    Gut 52:1535-6. 2003
  8. ncbi request reprint Non-steroidal anti-inflammatory and cyclooxygenase-2-selective inhibitors in clinical cancer prevention trials
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, Bethesda, MD, USA
    Prog Exp Tumor Res 37:210-42. 2003
  9. ncbi request reprint Epidemiology and prevention of colorectal cancer
    Ernest T Hawk
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Surg Clin North Am 82:905-41. 2002
    ..The challenges and rewards of participation in chemoprevention research--both as patients and health care providers-have never been greater...
  10. ncbi request reprint Chemoprevention of colorectal carcinogenesis
    Asad Umar
    Gastrointestinal and Other Cancers Research Group, National Cancer Institute, Division of Cancer Prevention, EPN, Suite 2141, 6130 Executive Boulevard, Bethesda, MD 20892 7317, USA
    Int J Clin Oncol 7:2-26. 2002
    ..These targets will help identify more effective and better tolerated preventive agents. Carcinogenesis is now recognized as a disease in itself and has become the target of an ever-expanding array of preventive interventions...
  11. ncbi request reprint Biomarkers as surrogates for cancer development
    E Hawk
    DCP GI and Other Cancer Research Group, National Cancer Institute, EPN, Suite 201, 6130 Executive Boulevard, Bethesda, MD 20892 7322, USA
    Curr Oncol Rep 2:242-50. 2000
    ..A step-wise approach to the development of tissue-based biomarkers is presented. These biomarkers may serve as molecular targets for scientific inquiry and intervention, as well as approvable endpoints for clinical trials...
  12. ncbi request reprint Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, Boston, Mass 02115, USA
    Circulation 114:1028-35. 2006
    ..Cyclooxygenase-2 (COX-2) inhibitors have been shown to reduce colorectal adenomas but have been associated with increased cardiovascular risk...
  13. ncbi request reprint Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention
    Scott D Solomon
    Cardiovascular Division, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    N Engl J Med 352:1071-80. 2005
    ..Experimental research suggesting that these drugs may contribute to a prothrombotic state provides support for this concern...
  14. ncbi request reprint The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress
    Ernest Hawk
    Cancer Epidemiol Biomarkers Prev 16:185-7. 2007
  15. ncbi request reprint Cancer prevention and the American Society of Clinical Oncology
    Scott M Lippman
    The University of Texas M D Anderson Cancer Center, Houston, USA
    J Clin Oncol 22:3848-51. 2004
  16. ncbi request reprint Colorectal cancer screening for persons at average risk
    William F Anderson
    Division of Cancer Prevention Gastrointestinal and Other Cancer Research Group, National Cancer Institute, Bethesda, MD 20892 7117, USA
    J Natl Cancer Inst 94:1126-33. 2002
  17. ncbi request reprint Statins and cancer prevention
    Marie France Demierre
    Department of Dermatology, Boston University School of Medicine, 720 Harrison Avenue DOB 801A, Boston, MA 02118, USA
    Nat Rev Cancer 5:930-42. 2005
    ..This understanding might also help the development of drugs for other ageing-related diseases with interrelated molecular pathways...
  18. pmc Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial
    Elisabeth I Heath
    Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
    J Natl Cancer Inst 99:545-57. 2007
    ....
  19. ncbi request reprint Celecoxib treatment alters the gene expression profile of normal colonic mucosa
    Oleg K Glebov
    Genetics Branch, Center for Cancer Research, National Naval Medical Center, Bethesda, Maryland, USA
    Cancer Epidemiol Biomarkers Prev 15:1382-91. 2006
    ....
  20. ncbi request reprint Statins and cancer--beyond the "one drug, one disease" model
    Ernest Hawk
    N Engl J Med 352:2238-9. 2005
  21. ncbi request reprint The critical role of risk-benefit assessments in cancer prevention
    Ernest Hawk
    Cancer Epidemiol Biomarkers Prev 14:297-8. 2005
  22. ncbi request reprint A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia
    Stephen Lam
    Department of Respiratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    J Natl Cancer Inst 94:1001-9. 2002
    ..We conducted a phase IIb study to determine the effects of ADT in smokers with bronchial dysplasia...
  23. ncbi request reprint A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium
    Stephen Lam
    Department of Respiratory Medicine, British Columbia Cancer Agency and the University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 10:6502-11. 2004
    ..Preclinical studies suggest that inhaled budesonide may be an effective chemopreventive agent for lung cancer. We conducted a phase IIb study to determine the effects of inhaled budesonide in smokers with bronchial dysplasia...
  24. pmc Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis
    Scott D Solomon
    Cardiovascular Division, Brigham and Women s Hospital, 75 Francis St, Boston, MA 02115, USA
    Circulation 117:2104-13. 2008
    ..Our aim was to assess the cardiovascular risk associated with celecoxib in 3 dose regimens and to assess the relationship between baseline cardiovascular risk and effect of celecoxib on cardiovascular events...